Repro-Med Systems (OTCMKTS:REPR) posted its quarterly earnings results on Tuesday. The company reported $0.00 EPS for the quarter, missing the Zacks’ consensus estimate of $0.02 by ($0.02), MarketWatch Earnings reports. The company had revenue of $5.35 million during the quarter. Repro-Med Systems had a net margin of 2.38% and a return on equity of 12.29%.
REPR stock traded up $0.25 during midday trading on Wednesday, reaching $3.30. The company had a trading volume of 50,180 shares, compared to its average volume of 50,395. The company’s 50 day simple moving average is $2.98. Repro-Med Systems has a 1-year low of $1.18 and a 1-year high of $3.33. The company has a quick ratio of 3.48, a current ratio of 4.72 and a debt-to-equity ratio of 0.04.
Separately, Craig Hallum assumed coverage on Repro-Med Systems in a research note on Thursday, June 20th. They issued a “buy” rating for the company.
Repro Med Systems, Inc, doing business as RMS Medical Products, designs, manufactures, and markets portable medical devices primarily for the ambulatory infusion market in the United States and internationally. The company offers mechanical infusion product comprising the FREEDOM infusion systems that include the FREEDOM60 syringe driver, the FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and RMS precision flow rate tubing.
Read More: Holder of Record
Receive News & Ratings for Repro-Med Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repro-Med Systems and related companies with MarketBeat.com's FREE daily email newsletter.